GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM

Based on the wide-ranging beneficial effects of GLP-1 RAs, the management of T2DM is no longer based on glucose control alone. The most recent ADA guidelines for T2DM provide guidance on drug- and patient-specific factors to consider when selecting an antihyperglycemic agent and therapeutic algorithms that center on a patient’s cardiovascular and renal profiles.


Program Content


  • Metabolic Effects and Their Role in Managing T2DM
    GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 30, 2022

    Expires: August 30, 2023

    View Activity


cover img faculity

Lucia M. Novak, MSN, ANP-BC, BC-ADM

Nurse Practitioner
Board Certified Adult Health and Advanced Diabetes Management
President and Owner
Diabetes Consulting Services
North Bethesda, Maryland
Co-Executive Director
Capital Health & Metabolic Center
Capital Diabetes & Endocrine Associates
Camp Springs and Silver Spring, Maryland

cover img faculity

Jay H. Shubrook, DO, FACOFP, FAAFP

Department of Clinical Sciences and Community Health
Touro University California
College of Osteopathic Medicine
Vallejo, California

cover img faculity

John White, Jr., PA-C, PharmD

Chair and R. Keith Campbell Distinguished Professor in Diabetes Care
Department of Pharmacotherapy
Washington State University College of Pharmacy and Pharmaceutical Sciences
Pullman, WA

cover img faculity

Eugene Wright, MD

Medical Director, Performance Improvement
Charlotte AHEC
Charlotte, NC

Provided by

ProCE Banner
ProCE Banner

Jointly provided by the Potomac Center for Medical Education and Rockpointe.


This activity is supported by an educational grant from Novo Nordisk.

Novo Nordisk